2026 SGO/SAGES Clinical Practice Statement: The Role of Metabolic and Bariatric Surgery for Obesity Management in Endometrial Intraepithelial Neoplasia and Endometrial Cancer

Full title: The role of metabolic and bariatric surgery for obesity management in endometrial intraepithelial neoplasia and endometrial cancer: A Society of Gynecologic Oncology and Society of American Gastrointestinal and Endoscopic Surgeons clinical practice statement Published: August 2026, Gynecologic Oncology Issuers: Society of Gynecologic Oncology (SGO) + Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Core positioning: Joint multidisciplinary oncologic-metabolic statement. It integrates obesity management into gynecologic oncology care for EIN (endometrial intraepithelial neoplasia) and endometrial carcinoma (EC). MBS (metabolic and bariatric surgery) is NOT a direct cancer resection operation, it is a modality to treat underlying adiposity, reduce perioperative risk, improve metabolic milieu and lower long-term recurrence risk; it works together with gynecologic oncologic therapy (hysterectomy or fertility-sparing progestin therapy).

1. Background & Core Pathophysiology

Obesity is the strongest modifiable risk factor for type I estrogen-driven endometrial disease (EIN, low-grade endometrioid EC). Adipose aromatase increases peripheral estrogen production, insulin resistance and hyperinsulinemia further stimulate endometrial proliferation.

• Obesity increases surgical risk and may make minimally invasive gynecologic oncologic surgery technically infeasible;
• Long-term mortality in obese EC patients often comes from cardiometabolic disease rather than cancer recurrence;
• Traditional siloed care separates oncology and weight management; this statement aims to build a unified MDT pathway.

2. Patient Eligibility & Indications for MBS

✅ Indications

1. EIN / early-stage, low-grade endometrioid EC, fertility-sparing candidates BMI ≥30, lifestyle + pharmacologic weight loss insufficient. MBS is adjunctive to progestin therapy; weight loss reduces endometrial hyperplasia and improves response to hormonal treatment.
2. Severely obese patients (usually BMI ≥40, or BMI ≥35 with T2DM/OSA/HTN) with EIN/early EC, too high risk for immediate definitive gynecologic surgery MBS as prehabilitation: achieve substantial weight loss, improve cardiopulmonary/metabolic status, then perform hysterectomy after 6–12 months.
3. Concurrent combined surgery (selected patients, MDT decision) Same-stage laparoscopic hysterectomy + MBS, in carefully screened low-risk patients, performed by dual gynecologic oncology + bariatric team.
4. Completed oncologic treatment (post-hysterectomy EIN/EC survivors) Persistent severe obesity, to reduce metabolic comorbidities and secondary metachronous cancer risk (breast, colon).

NOT indicated: High-risk histology (serous, clear cell, carcinosarcoma), advanced/metastatic endometrial cancer, active uncontrolled malignancy requiring urgent oncologic resection.

MBS candidate standard criteria

Align with global bariatric criteria:

• BMI ≥40; OR BMI ≥35 plus obesity-related comorbidities (T2DM, hypertension, OSA, metabolic syndrome);
• Failed structured lifestyle intervention;
• No contraindications to bariatric operation;
• MDT evaluation: gynecologic oncologist, bariatric surgeon, endocrinologist, nutritionist, mental health provider.

3. Weight Management Hierarchy (stepwise approach)

1. First tier: lifestyle modification (diet, physical activity, behavioral counselling) for all patients.
2. Second tier: pharmacotherapy (GLP‑1RA / GIP-GLP‑1 dual agonists). The statement recognizes GLP‑1 agents as important adjunct for fertility-sparing EIN/early EC, improving progestin response.
3. Third tier: MBS, for those failing above measures and meeting BMI criteria.

Key message: MBS is the most durable intervention for sustained weight loss in this population.

4. Timing Strategies of MBS (3 clinical pathways)

Pathway 1: MBS first (prehabilitation) → delayed gynecologic oncologic surgery

For morbid obesity where immediate hysterectomy carries excessive anesthetic/surgical risk. Target substantial weight loss over 6–12 months, then definitive hysterectomy.

Caveat: close endometrial surveillance during waiting period (endometrial sampling every 3–6 months).

Pathway 2: Same-session combined surgery

Selected low-risk EIN / stage IA grade1 EC, well-selected patient, experienced dual-team center. Benefit: single anesthesia, simultaneous cancer treatment and metabolic intervention.

Caution: higher operative complexity, only in high-volume MDT centers, not for widespread routine use.

Pathway3: MBS during fertility-sparing hormonal management

EIN / grade 1 early EC desiring fertility preservation. MBS + progestin/IUD hormonal therapy; serial endometrial biopsy monitoring. Weight loss improves endometrial regression rate. Pregnancy planning is deferred until stable weight and endometrial remission.

5. Preferred Bariatric Procedures

1. Roux-en-Y gastric bypass (RYGB) – robust weight loss, strong improvement of insulin resistance, well-studied in endometrial hyperplasia/early EC cohorts.
2. Sleeve gastrectomy (SG) – most commonly performed; good weight loss and metabolic improvement, technically simpler.

Adjustable gastric band is less preferred due to slower, modest weight loss and higher revision rate.

6. Pre-procedure MDT Assessment & Baseline Workup

1. Oncologic staging: biopsy pathology, MRI/US, tumor subtype, MMR/MSI status; rule out high-risk histology.
2. Metabolic panel: HbA1c, lipid, liver function, vitamin levels, OSA screening, cardiac risk stratification.
3. Nutritional & psychological assessment, eating disorder screening.
4. Fertility counselling for reproductive-age women.

7. Post-operative Surveillance & Nutritional Long-term Care

1. Oncologic surveillance:
   • Fertility-sparing group: endometrial sampling every 3–6 months;
   • Post-hysterectomy survivors: standard EC surveillance plus metabolic monitoring.
2. Bariatric long-term follow-up:
   • Multivitamin, iron, calcium, vitamin D lifelong supplementation;
   • Nutrition monitoring, protein intake, body composition assessment;
   • Monitor weight regain, insulin resistance, lipid profile.

Weight regain after MBS may increase risk of recurrent endometrial hyperplasia, so sustained metabolic follow-up is mandatory.

8. Safety & Key Risks

1. Perioperative risks: anastomotic leak, bleeding, DVT/PE, nutritional deficiencies (iron, B12, calcium, vitamin D).
2. Oncologic caution: MBS does not directly remove endometrial lesion. Even after substantial weight loss, malignant/pre-malignant endometrial tissue may persist. Never rely on MBS alone for cancer treatment.
3. Pregnancy risk after MBS: pregnancy should be planned after weight stabilization, with high-risk obstetric follow-up and nutritional monitoring.

9. Evidence Gaps & Controversies

1. No large randomized controlled trials comparing MBS vs pharmacologic weight loss on endometrial cancer recurrence. Current evidence mainly from retrospective cohorts and case series.
2. Long-term (＞10 years) oncologic recurrence data after combined MBS + fertility-sparing management remains limited.
3. Unclear optimal threshold of weight loss magnitude required for maximal endometrial regression.
4. Real-world access barriers: MDT centers, insurance coverage, long-term nutrition follow-up.

10. Cross alignment with prior guideline series

1. This SGO/SAGES 2026 statement: gynecologic oncology + bariatric surgery for EIN/early EC obese women, integrating metabolic surgery into gynecologic oncology care.
2. 《Chinese Adult Weight Management Guideline (2025)》: general adult obesity intervention, this statement provides specialized oncologic subpopulation recommendations.
3. SMS 2026 menopause obesity statement: peri/postmenopausal women and 肠促胰岛素 therapy; this document focuses on endometrial neoplasia, fertility preservation and MBS.
4. BMJ living T2D guideline / EASO 2026 incretin position: GLP‑1/GIP-GLP‑1 metabolic and weight-lowering pharmacology, which is the second-tier option in this SGO/SAGES pathway.

Disclaimer: This summary is for academic study only, not for direct clinical practice. MBS plus gynecologic oncologic management requires multidisciplinary evaluation at high-volume specialized centers.